
William A. Faubion
Consultant, Division of Gastroenterology and Hepatology, Department of Internal Medicine · Mayo Clinic
Credentials: · · · ·
History
- Present
Center for Basic Research in Digestive Diseases, Mayo Clinic Rochester Centers




Research
Gastroenterology · 2001 · First of 5 authors · 889 citations
JAK-STAT pathway targeting for the treatment of inflammatory bowel disease
Review · Nature Reviews Gastroenterology & Hepatology · 2020 · 555 citations
Toxic bile salts induce rodent hepatocyte apoptosis via direct activation of Fas
Journal of Clinical Investigation · 1999 · First of 8 authors · 459 citations

31 papers
- LR
23 papers

22 papers · 6 as a resident

20 papers
- WT
19 papers
- DB
17 papers · 2 as a fellow
- SK
15 papers
- KP
14 papers
Grants
- 2010–2027
Inflammatory Cascades Disrupt Treg Function Through Epigenetic Mechanisms
National Institute of Allergy and Infectious Diseases · R01
Contact PI · $6.3M · Mayo Clinic Arizona
- 2009–2024
Mayo Center for Cell Signaling in Gastroenterology
National Institute of Diabetes and Digestive and Kidney Diseases · P30
Project lead · $704.3K · Mayo Clinic Rochester
- 1979–2023
Multidisciplinary Training in Digestive Diseases
National Institute of Diabetes and Digestive and Kidney Diseases · T32
Contact PI · $3.6M · Mayo Clinic Rochester
- 2010–2011
KLF10 Regulates Colitis Through Mediating TGFb Induction of FOXP3 in Treg Cells.
National Institute of Allergy and Infectious Diseases · R56
Contact PI · $394.3K · Mayo Clinic Rochester
Clinical trials
- 2020–2026
Angiographic Delivery of AD-MSC for Ulcerative Colitis
Principal investigator · Active not recruiting · Phase 1
Mayo Clinic
- 2019–2024
Novel Stomal Occlusion Device in Patients With a Brooke Ileostomy
Principal investigator · Completed
William A. Faubion, M.D.
- 2017–2019
Re-treatment From a Phase I Study of MSC-AFP in Patients With Perianal Fistulas
Principal investigator · Completed · Phase 1
William A. Faubion, M.D.
- 2017–2020
Phase 1 Crohn's Pediatric Sub-study of MSC AFP
Principal investigator · Withdrawn · Phase 1
William A. Faubion, M.D.
